[Pleiotropic Effects of Rosuvastatin in Chronic Obstructive Pulmonary Disease Patients With High Cardiovascular Risk].

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the list of common causes of mortality after cardiovascular diseases. The processes of atherogenesis and cardiovascular diseases are accelerated in patients with COPD. The key mechanisms of COPD pathogenesis are oxidative stress, depletion of antioxidant protection, development of the pulmonary and systemic inflammation and the development of endothelial dysfunction.

[Pleiotropic Effects of Rosuvastatin in Patients With High Cardiovascular Risk].

hronic obstructive pulmonary disease (COPD) is the third leading cause of death in the list of common causes of mortality after cardiovascular diseases. The processes of atherogenesis and cardiovascular diseases are accelerated in patients with COPD. The key mechanisms of COPD pathogenesis are oxidative stress, depletion of antioxidant protection, development of the pulmonary and systemic inflammation and the development of endothelial dysfunction.

[Modern tactics antihypertensive therapy: a place of Angiotensin converting enzyme inhibitors].

In a review article we presents an analysis of the new recommendations of the European Society of hypertension (ESH) and the European Society of Cardiology (ESC) on the management of arterial hypertension (2013). Main attention is paid to the tactics of antihypertensive therapy and the choice of drugs in the treatment of early hypertension. Target blood pressure levels in are discussed the historical aspect.

[What is the optimal choice of antihypertensive therapy based on: the class-specific effects or special properties of a drug?].

The review article presents data on the significance of activation of different components of the renin-angiotensin-aldosterone system (RAAS) in metabolic disorder progression and organ damage processes. Based on the analysis of the pharmacological properties of drugs and clinical evidence, the authors discuss the problems of the choice of RAAS blockers. The mechanisms of drug action on metabolic processes, atherogenesis, and vascular damage are discussed.